effective-component compatibility of bufei yishen formula II

**ECC-BYF II** is an optimized multicomponent Traditional Chinese Medicine (TCM) preparation derived from the Bufei Yishen formula (BYF), which is used in studies for chronic obstructive pulmonary disease (COPD). It comprises a specific combination of five bioactive compounds: paeonol, icariin, nobiletin, total ginsenoside, and astragaloside IV[1]. **Mechanism of Action**: ECC-BYF II has demonstrated efficacy in improving pulmonary function, reducing inflammation, oxidative stress, mucus hypersecretion, and abnormal airway remodeling in COPD animal models. Its mechanism involves significant downregulation of the EGFR/PI3K/mTOR signaling pathway, which is key in mucus hypersecretion and airway inflammation in COPD[1]. **Primary Indication**: Investigated for the treatment of COPD, particularly for reducing mucus hypersecretion and improving lung function in preclinical models[1].